143
Views
0
CrossRef citations to date
0
Altmetric
Real-World Evidence

Real-world clinical outcomes and healthcare costs in patients with Crohn’s disease treated with vedolizumab versus ustekinumab in the United States

, , , , , , , , & show all
Pages 877-885 | Received 13 Jul 2023, Accepted 29 Feb 2024, Published online: 08 Apr 2024